2023
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial.
Lansky A, Xu B, Baumbach A, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson T, Vlachojannis G, Arkenbout K, Holmvang L, Janssens L, Brugaletta S, Naber C, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Wijns W. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial. EuroIntervention 2023, 19: e844-e855. PMID: 37860860, PMCID: PMC10687649, DOI: 10.4244/eij-d-23-00409.Peer-Reviewed Original ResearchConceptsTarget lesion failureDP-EES groupPercutaneous coronary interventionBP-SES groupBP-SESPrimary endpointDP-EESRate of TLFBiodegradable polymer sirolimus-eluting stentsST-elevation myocardial infarction (STEMI) presentationMyocardial infarction presentationSirolimus-eluting stentsFive-year resultsLong-term safetyAbluminal grooveLesion failureSecondary endpointsComers populationCoronary interventionMyocardial ischaemiaStent implantationClinical trialsTargeted therapyLandmark analysisStudy outcomes
2019
Validation of the all-comers design: Results of the TARGET-AC substudy
G Toth G, Lansky A, Baumbach A, Kelbæk H, van Royen N, Holmvang L, Janssens L, Brugaletta S, Barbato E, Maillard L, Kiemeneij F, Naber CK, Pucher F, Laursen PN, Ameloot K, Robles C, Milkas A, Sevilla J, Jensen C, Wijns W. Validation of the all-comers design: Results of the TARGET-AC substudy. American Heart Journal 2019, 221: 148-154. PMID: 31924299, DOI: 10.1016/j.ahj.2019.10.019.Peer-Reviewed Original ResearchConceptsComers designRisk factorsNon-ST elevation acute coronary syndromeElevation acute coronary syndromeNER groupReal-world clinical practiceGroup more patientsInternational multicentre registrySignificant valvular diseaseST-elevation infarctionAcute coronary syndromeChronic total occlusionWorld clinical practiceLow inclusion rateMulticentre registryThrombotic stenosisCoronary syndromePrimary PCIStable anginaAngiographic parametersComers populationPatient demographicsStable patientsStudy nursesMore patients
2018
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial
Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A, Investigators T. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. The Lancet 2018, 392: 1117-1126. PMID: 30190206, DOI: 10.1016/s0140-6736(18)31649-0.Peer-Reviewed Original ResearchConceptsLate lumen lossStent late lumen lossTarget lesion failureCoronary artery diseaseNon-inferiority trialXience groupPrimary endpointLesion failureLumen lossAbluminal grooveAngiographic substudyComers populationArtery diseaseMyocardial ischaemiaMyocardial infarctionIschaemia-driven target lesion revascularisationAsymptomatic coronary artery diseaseTarget vessel myocardial infarctionIschemic coronary artery diseaseST-elevation myocardial infarctionRandom block allocationTarget lesion revascularisationStent thrombosis ratesVessel myocardial infarctionElevation myocardial infarction